경피적 심장판막 시장 : 밸브 종류, 시술 종류, 기술, 재료 종류, 최종사용자, 유통 채널별 - 세계 예측(2026-2032년)

The Transcatheter Heart Valve Market is projected to grow by USD 12.43 billion at a CAGR of 12.02% by 2032.

Transcatheter heart valve therapies, led by transcatheter aortic valve replacement (TAVR/TAVI), have moved from a high-risk surgical alternative to a mainstream structural heart intervention for selected patients with severe symptomatic aortic stenosis. The market is supported by well-established clinical evidence, expanding guideline eligibility, aging demographics, and the need to reduce hospitalization burden in cardiovascular care.

Demand is anchored in measurable epidemiology: the World Health Organization identifies cardiovascular disease as the world's leading cause of death, while the United Nations projects the global population aged 65 and older to more than double by 2050. Because calcific aortic stenosis and other valve disorders rise sharply with age, transcatheter heart valve adoption is positioned as a durable growth area across hospitals, ambulatory cardiac programs, and integrated health systems.

Transformative Shifts in the Transcatheter Valve Landscape

The transcatheter heart valve landscape is being reshaped by broader indications, next-generation delivery systems, improved imaging, and operator experience. Randomized trials and real-world registries have established TAVR as a guideline-supported option across multiple surgical-risk profiles in appropriately selected patients, shifting the competitive focus from procedural feasibility to long-term durability, lifetime valve management, and patient selection.

Competitive differentiation increasingly depends on low-profile delivery, repositionability, sealing technology to reduce paravalvular leak, predictable coronary access, and compatibility with valve-in-valve procedures. Hospitals are also reorganizing structural heart programs around multidisciplinary heart teams, hybrid operating rooms, advanced CT planning, cerebral protection evaluation, and post-procedure pathways that support shorter length of stay without compromising safety.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative advantage across the transcatheter heart valve value chain. AI-enabled CT segmentation, echocardiography interpretation, annular measurement, calcium scoring, and access-route assessment can reduce planning variability and support more consistent valve sizing. These tools are especially relevant as programs treat older patients with complex anatomy, bicuspid valves, prior bioprostheses, and multivalve disease.

The commercial impact of AI is also expanding into workflow automation, inventory planning, physician training, post-market surveillance, and remote patient monitoring. Industry leaders must align AI development with FDA, EU MDR, and Good Machine Learning Practice expectations, because transparent validation, bias management, cybersecurity, and clinically meaningful endpoints will determine adoption by hospitals and payers.

Key Regional Insights Across Global Markets

North America remains the most mature region for transcatheter heart valves due to established reimbursement, high procedural capacity, clinical registry infrastructure, and rapid adoption of FDA-approved device iterations. The United States anchors regional leadership through broad structural heart programs and registry-based quality tracking, while Canada's publicly funded system supports access through provincial assessment and hospital capacity planning.

Europe continues to be a major innovation and evidence-generation hub, although EU Medical Device Regulation requirements have increased the importance of post-market clinical follow-up, real-world performance data, and robust technical documentation. Asia-Pacific is the fastest-expanding opportunity base as Japan, China, India, South Korea, and Australia combine aging populations with investments in tertiary cardiac care, advanced imaging, and specialist training. Latin America is led by Brazil and Mexico but remains sensitive to reimbursement constraints, public-private access gaps, and uneven distribution of catheterization laboratories. The Middle East is expanding through advanced cardiac centers in high-income health systems, particularly where national health strategies prioritize minimally invasive cardiovascular care, while Africa's adoption remains limited by infrastructure, specialist availability, and affordability, creating a need for targeted training, referral networks, and sustainable access models.

Key Group Insights for Strategic Market Prioritization

Within ASEAN, transcatheter heart valve growth is supported by expanding private healthcare networks, medical tourism centers, and investments in tertiary cardiac hospitals, although reimbursement coverage, imaging access, and specialist density differ widely across member states. The GCC benefits from high healthcare spending, hospital modernization, and demand for minimally invasive cardiac procedures, making it attractive for premium transcatheter valve platforms, clinician education partnerships, and regional centers of excellence.

The European Union is shaped by MDR compliance, health technology assessment, evidence-based procurement, and an increasing requirement for long-term clinical follow-up. BRICS markets combine large patient pools, rising cardiovascular disease burden, and expanding hospital infrastructure with price sensitivity and localization priorities, requiring differentiated portfolio, training, and manufacturing strategies. G7 countries set clinical evidence, reimbursement, quality registry, and guideline adoption benchmarks that influence global practice patterns, while NATO member markets reinforce the importance of resilient supply chains, cybersecurity, regulatory alignment, and cross-border medical technology standards for high-value cardiovascular devices.

Key Country Insights in High-Priority Markets

The United States leads global transcatheter heart valve adoption through strong clinical evidence, CMS coverage pathways, FDA-approved device availability, and the STS/ACC TVT Registry, which supports outcomes monitoring and quality improvement. Canada offers stable public reimbursement but requires provincial access planning and capacity coordination. Mexico and Brazil are important Latin American entry points, with adoption concentrated in advanced urban cardiac centers and influenced by public-private financing dynamics, specialist availability, and health system prioritization of structural heart disease.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain significant structural heart programs supported by guideline-based care, established interventional cardiology capacity, and aging populations. Germany's high procedural capacity and hospital infrastructure remain influential, while France's evidence-driven reimbursement environment supports structured evaluation of clinical value. The United Kingdom emphasizes health technology assessment and pathway efficiency, Italy and Spain continue to expand access through regional cardiac networks, and Russia presents access, procurement, and supply-chain complexity. In Asia-Pacific, China is scaling local innovation, hospital capacity, and regulatory approvals; India is expanding selective adoption amid affordability and reimbursement constraints; Japan has mature regulatory pathways and strong aging-driven demand; Australia supports evidence-based access through advanced public and private hospital systems; and South Korea combines advanced hospitals, digital health readiness, and rapid uptake of cardiovascular technology.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation beyond initial safety and efficacy, including long-term valve durability, coronary reaccess, valve-in-valve feasibility, stroke reduction, pacemaker rates, paravalvular leak reduction, hemodynamic performance, and outcomes in younger low-risk patients. Clear differentiation is needed as hospitals and payers increasingly evaluate total cost of care, procedural efficiency, length of stay, readmission avoidance, and long-term reintervention risk.

Commercial teams should build region-specific access strategies, invest in heart-team training, strengthen AI-enabled planning capabilities, and ensure supply continuity for valves, delivery systems, and imaging-compatible accessories. Partnerships with registry networks, academic centers, payers, and clinical training institutions can accelerate adoption while supporting transparent post-market surveillance, real-world evidence generation, value-based contracting, and responsible expansion into underpenetrated care settings.

Research Methodology and Data Validation

This executive summary is developed using a triangulated research approach that integrates regulatory databases, clinical guidelines, peer-reviewed trials, post-market registries, reimbursement policies, and demographic datasets. Priority sources include FDA, European regulatory and EU MDR documentation, national health agencies, WHO, UN population data, OECD health indicators, ACC/AHA and ESC/EACTS guidelines, and structural heart registries such as the STS/ACC TVT Registry.

The methodology emphasizes verified, data-backed insights and excludes unsupported market claims, market sizing, market share, or forecasting. Findings are validated through cross-source comparison of clinical evidence, device approvals, access pathways, hospital adoption indicators, demographic drivers, and regional healthcare capacity to ensure that conclusions are commercially relevant, reproducible, and defensible.

Conclusion and Strategic Outlook

The transcatheter heart valve market is entering a more sophisticated phase defined by broader patient eligibility, rising durability expectations, AI-assisted planning, and differentiated reimbursement scrutiny. Growth is no longer driven only by procedural expansion; it increasingly depends on measurable clinical value, workflow efficiency, anatomical precision, and lifetime valve management.

Organizations that combine strong clinical evidence with regional access strategies, intelligent digital tools, resilient supply chains, and physician education will be best positioned to lead. As population aging accelerates and health systems seek less invasive cardiovascular solutions, transcatheter heart valves will remain central to the future of structural heart disease treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Transcatheter Heart Valve Market, by Valve Type

• 7.1. Transcatheter Aortic Valves
• 7.2. Transcatheter Mitral Valves
• 7.3. Transcatheter Pulmonary Valves
• 7.4. Transcatheter Tricuspid Valves

8. Transcatheter Heart Valve Market, by Procedure Type

• 8.1. Valve Replacement Procedures
• 8.2. Valve Repair Procedures

9. Transcatheter Heart Valve Market, by Technology

• 9.1. Balloon-Expandable Technology
• 9.2. Self-Expanding Technology
• 9.3. Mechanically Expandable Technology
• 9.4. Polymer-Based Valve Technology

10. Transcatheter Heart Valve Market, by Material Type

• 10.1. Nitinol-Based Valves
• 10.2. Stainless Steel Valves
• 10.3. Cobalt-Chromium Valves
• 10.4. Polymer-Based Valves

11. Transcatheter Heart Valve Market, by End User

• 11.1. Cardiac Catheterization Laboratories
• 11.2. Hospitals
  • 11.2.1. Public Hospitals
  • 11.2.2. Private Hospitals
• 11.3. Ambulatory Surgical Centers

12. Transcatheter Heart Valve Market, by Distribution Channel

• 12.1. Online
• 12.2. Offline

13. Transcatheter Heart Valve Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Transcatheter Heart Valve Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Transcatheter Heart Valve Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Anteris Technologies Ltd
• 17.3. Blue Sail Medical Co., Ltd.
• 17.4. Boston Scientific Corporation
• 17.5. Cardiovalve Ltd.
• 17.6. Colibri Heart Valve, LLC
• 17.7. Edwards Lifesciences Corporation
• 17.8. Foldax, Inc.
• 17.9. HighLife SAS
• 17.10. JenaValve Technology, Inc.
• 17.11. LivaNova PLC
• 17.12. Medtronic plc
• 17.13. Meril Life Sciences Pvt. Ltd.
• 17.14. MicroPort CardioFlow Medtech Corporation
• 17.15. Peijia Medical Limited
• 17.16. Pi-Cardia Ltd.
• 17.17. Tioga Cardiovascular
• 17.18. TRiCares GmbH
• 17.19. Venus Medtech (Hangzhou) Inc.
• 17.20. Xeltis B.V.